Pancreatic Cancer Diagnostic Approach

Definition and Etiology

• The American Joint Committee on Cancer (AJCC) states that adenocarcinoma represents more than 90% of pancreatic malignancies, with more than 80% exhibiting KRAS mutations and approximately 90% showing alterations in the CDKN2 gene 1
• The National Comprehensive Cancer Network (NCCN) guidelines indicate that most tumors (60-70%) are located in the head of the pancreas, 20-25% in the body, and 5-10% in the tail 1

Diagnostic Criteria and Clinical Presentation

• The NCCN recommends considering pancreatic cancer in adult-onset diabetes without predisposing factors or family history 2, 3, 5
• The European Society for Medical Oncology (ESMO) states that cardinal symptoms include weight loss, painless jaundice (head tumors), abdominal or back pain, steatorrhea, nausea, and depression, although no early warning signs are established 4, 3

Diagnostic Imaging Algorithm

Ultrasonography (Abdominal Ultrasound)

• The NCCN suggests that a suggestive clinical presentation of pancreatic cancer should promptly lead to liver, biliary, and pancreatic ultrasound as the initial study 2, 5
• The American College of Radiology (ACR) states that advantages include accessibility, non-invasiveness, and usefulness for initial evaluation and detection of biliary duct dilation 2, 5

Computed Tomography (CT)

• The NCCN recommends CT as the primary imaging modality for diagnosis and staging, with a multidetector CT using a pancreatic trifasic protocol (arterial, late arterial, and venous phases) being the most validated and widely available method 3, 4
• The American College of Radiology (ACR) states that CT has a sensitivity of 70-85% for detecting resectable tumors and is the standard of care recommended by all NCCN institutions 3, 4

Magnetic Resonance Imaging (MRI)

• The NCCN suggests using MRI with gadolinium combined with magnetic resonance cholangiopancreatography (MRCP) when CT is contraindicated or as a complement to distinguish solid masses from cystic lesions and detect extrapancreatic disease in high-risk patients 1, 3, 4, 6
• The European Society for Medical Oncology (ESMO) states that MRI has advantages over CT for detecting small hepatic metastases and peritoneal metastases 7

Histological Diagnosis

• The NCCN states that histological confirmation is mandatory in non-resectable cases or when neoadjuvant therapy is planned but not necessary before curative surgery if the clinical and imaging presentation is typical 1, 6, 8
• The American Gastroenterological Association (AGA) recommends attempting to obtain tissue diagnosis during endoscopic procedures 2, 5

Tumor Markers

• The NCCN states that CA19-9 has limited diagnostic value and should not be used as a primary diagnostic tool due to lack of specificity and false negatives in patients without Lewis antigen 1, 6
• The European Society for Medical Oncology (ESMO) suggests that CA19-9 can be used to guide treatment and follow-up, with prognostic value in the absence of cholestasis 1

Staging and Resectability Evaluation

• The NCCN recommends CT as the primary means of staging pancreatic cancer, unlike other cancers where staging is primarily surgical 3, 4
• The American College of Radiology (ACR) states that CT chest should be used to evaluate pulmonary metastases 8

High-Risk Populations for Screening

• The NCCN suggests that asymptomatic high-risk individuals (first-degree relatives with cancer, hereditary syndromes such as BRCA2, CDKN2A, PALB2) should undergo regular EUS and MRI for early detection 3, 6
• The International Cancer of the Pancreas Screening (CAPS) Consortium states that EUS can detect preinvasive neoplasias in high-risk individuals 3

Specific Recommendations for Biliary Obstruction Management

• The NCCN recommends that most patients requiring relief of obstructive jaundice are adequately treated with endoscopic plastic stenting; surgical bypass may be preferred in patients with a life expectancy of more than 6 months 2, 5
• The American Society for Gastrointestinal Endoscopy (ASGE) states that endoscopic stent placement is preferable to transhepatic stenting 2, 5, 8